These results provide evidence supporting the pharmacological application of NRF2 inhibitors, such as ML385 and brusatol, for the prevention of distant melanoma metastasis and treatment of metastatic melanoma, although some deficiencies in these compounds remain.32 The gene discussed is NFE2L2; the disease is melanoma.